Advancing Neuroscience Through Strategic Partnerships
By working with the most respected names in neuroscience research, we're not just developing diagnostic tools—we’re helping define the role of synucleinopathies across the neurodegenerative landscape.
Amprion Partners
In 2023, the Michael J. Fox Foundation announced a breakthrough facilitated by the Amprion SAAmplify-αSYN test, saying it “heralds the revolutionary ability for research to define Parkinson’s disease biologically, offering a critical tool for clinical trial design and assessment of treatment effects, and for early detection of disease pathology.”
Partner With Us to Define the Involvement of α-Syn Throughout the NDD Landscape
Interested in leveraging the most sensitive and specific technology for detecting α-synuclein pathology? Join our network of prestigious research collaborators and pharmaceutical partners working to transform neurodegenerative disease detection and treatment. Complete the form below, and our scientific collaboration team will contact you.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
